Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shenzhen Stock Exchange
  5. Hangzhou Tigermed Consulting Co., Ltd
  6. Summary
    300347   CNE100001KV8

HANGZHOU TIGERMED CONSULTING CO., LTD

(300347)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Shenzhen Stock Exchange
01/13/2022 01/14/2022 01/17/2022 01/18/2022 01/19/2022 Date
123.14 123.32 121.08 122.02 118.9 Last
11159290 6465522 6490318 5151106 4705757 Volume
+3.06% +0.15% -1.82% +0.78% -2.56% Change
Estimated financial data (e)
Sales 2021 4 548 M 717 M 717 M
Net income 2021 2 262 M 357 M 357 M
Net cash position 2021 11 286 M 1 779 M 1 779 M
P/E ratio 2021 38,0x
Yield 2021 0,40%
Sales 2022 6 024 M 950 M 950 M
Net income 2022 2 614 M 412 M 412 M
Net cash position 2022 12 538 M 1 976 M 1 976 M
P/E ratio 2022 39,7x
Yield 2022 0,46%
Capitalization 97 277 M 15 331 M 15 334 M
EV / Sales 2021 18,9x
EV / Sales 2022 14,1x
Nbr of Employees -
Free-Float 68,6%
More Financials
Company
Hangzhou Tigermed Consulting Co, Ltd. specialises in providing professional services to pharmaceutical and biotech companies. The group supports its clients in all processes of clinical development and product commercialization. Net sales break down by activity as follows: - provision of clinical trial services and related technological services (51.8%); - provision of clinical research consulting services (48.2%). 
More about the company
Ratings of Hangzhou Tigermed Consulting Co., Ltd
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about HANGZHOU TIGERMED CONSULTING CO., LTD
01/13Hangzhou Tigermed Consulting Projects Higher FY2021 Profit
MT
01/12Hangzhou Tigermed Consulting Co., Ltd Provides Earnings Guidance for the Year of 2021
CI
01/04Hangzhou Tigermed Consulting Co., Ltd Announces Resignation of Wang Ruwei as Vice Gener..
CI
2021Shanghai OMNI Pharmaceutical Technology Co., Ltd. announced that it has received $31.4 ..
CI
2021HighField BioPharmaceuticals announced that it has received $31.4 million in funding fr..
CI
2021Beijing BioInno Bioscience Co., Ltd. announced that it has received $31.4 million in fu..
CI
2021JS InnoPharm Ltd. announced that it has received funding from a group of investors
CI
2021Tranche Update on Hangzhou Tigermed Consulting Co., Ltd's Equity Buyback Plan announced..
CI
2021Hangzhou Tigermed Consulting Co., Ltd's Equity Buyback announced on August 25, 2021, ha..
CI
2021HANGZHOU TIGERMED CONSULTING : Profit Jumps 35.1% on Higher Investment Income in January-S..
MT
2021Hangzhou Tigermed Consulting Co., Ltd Reports Earnings Results for the Nine Months Ende..
CI
2021Hangzhou Tigermed Consulting Co., Ltd Appoints Mr. Wu as an Executive Director
CI
2021Tranche Update on Hangzhou Tigermed Consulting Co., Ltd's Equity Buyback Plan announced..
CI
2021Hangzhou Tigermed Consulting Co., Ltd Announces Changes in Chief Financial Officer
CI
2021Hangzhou Tigermed Consulting Co., Ltd Announces Executive Changes
CI
More news
News in other languages on HANGZHOU TIGERMED CONSULTING CO., LTD
01/13Hangzhou Tigermed Consulting prévoit une hausse du bénéfice pour l'exercice 2021
01/12Hangzhou Tigermed Consulting Co., Ltd. fournit des prévisions de bénéfices pour l'année..
01/04Hangzhou Tigermed Consulting Co., Ltd annonce la démission de Wang Ruwei en tant que di..
2021Le bénéfice de Hangzhou Tigermed Consulting fait un bond de 35,1 % grâce à l'augmentati..
2021Tigermed enregistre une croissance à deux chiffres de ses bénéfices au premier semestre..
More news
Chart HANGZHOU TIGERMED CONSULTING CO., LTD
Duration : Period :
Hangzhou Tigermed Consulting Co., Ltd Technical Analysis Chart | 300347 | CNE100001KV8 | MarketScreener
Technical analysis trends HANGZHOU TIGERMED CONSULTING CO., LTD
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 18
Last Close Price 118,90 CNY
Average target price 191,55 CNY
Spread / Average Target 61,1%
EPS Revisions
Managers and Directors
Xiao Chun Cao Chief Financial Officer, Executive Director & GM
Hao Wu Co-President & Executive Director
Xiao Li Shi Chairman-Supervisory Board
Xiao Ping Ye Chairman
Bi Yun Zheng Independent Director
Sector and Competitors
1st jan.Capi. (M$)
HANGZHOU TIGERMED CONSULTING CO., LTD-6.96%15 331
MODERNA, INC.-26.53%75 661
LONZA GROUP AG-15.05%52 427
IQVIA HOLDINGS INC.-14.11%46 293
SEAGEN INC.-15.72%23 824
ICON PUBLIC LIMITED COMPANY-17.86%20 707